BILLERICA, Massachusetts – November 28, 2017– Bruker today announced a contract to deliver 133 RAID™ M-100 hand-held chemical detectors, which are based on Bruker’s advanced ion mobility spectrometry (IMS) technology, to the United States National Guard.
For deliveries through March 2018, the 133 RAID M-100 units upgrade and enhance the capabilities of the National Guard Homeland Response Force (HRF) and of the CBRNE Enhanced Response Force Package (CERFP). The RAID M-100s will replace older Chemical Agent Monitor (CAM) detectors that have been in service for many years.
The fast, sensitive and reliable response of the new RAID M-100 detectors will enhance mission capabilities of these strategic National Guard units, which are vital to national defense.
Mr. Frank Thibodeau, Vice President for Business Development for Bruker Detection Corporation, commented: “Bruker is very pleased to deliver this contract to such an important client, and it confirms our position as a key global supplier of chemical detection technologies for homeland security. Our RAID M-100 detectors are already in service with the National Guard Civil Support Teams (CST) nationwide.”
Bruker Detection Corporation is a leading provider of mobile, ruggedized and user-friendly CBRNE (Chemical, Biological, Radiological, Nuclear and Explosive) detection systems and solutions. Serving this demanding market for more than 30 years, Bruker Detection has built a reputation for delivering high quality, high performance and innovative solutions to its customers. For more information: www.bruker.com/cbrne
About Bruker Corporation (NASDAQ: BRKR)
For more than 55 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nanoanalysis and industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research, clinical microbiology and molecular pathology research. For more information, please visit: www.bruker.com
Miroslava Minkova Head of Investor Relations
T: +1 (978) 663–3660, ext. 1479
E: [email protected]
Bruker Detection Corporation
T: +1 (978) 663-3660, ext. 130
E: [email protected]